RxDoctor Payments Data

Jordan Ahnert

Cardiovascular Disease · Brunswick, GANPI 1124500939

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $1,947 of the $2,372 with a category attached, or 82.1%. Amgen accounts for 82.1% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2023 at $1,981 and has fallen 96.2% since, to $75 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in GA, where the typical reported total is $2,276.

$2,372in general payments, 2019–2025

Across 22 payments — averaging $107.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • Ambu Inc.$45
  • Boston Scientific$45
  • Davol Inc.$39
  • Endomagnetics Ltd$38
  • Bard Peripheral Vascular, Inc.$36
  • plus $223 from 12 others
$600,874in research payments, 2019–2025

Across 25 payments — averaging $24,035 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Beone Medicines AUS Pty Ltd$277K
  • Beigene AUS Pty Ltd$161K
  • Astrazeneca UK Limited$107K
  • AstraZeneca$55K
  • Incyte Corporation$1K

What the payments were for

  • Consulting fees$1,94782%
  • Food & beverage$42518%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,372 in reported general payments places this provider in the 50th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Other cardiovascular disease in Brunswick

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →